The company said net revenues for Q1 2025 were $13.343 billion, an increase of 8.4% on a reported basis and 9.8% on an operational basis. Net revenues from the immunology portfolio were $6.264 billion, up 16.6% on a reported basis. Skyrizi generated $3.425 billion and Rinvoq generated $1.718 billion.

1. 01

   The company said net revenues for Q1 2025 were $13.343 billion, an increase of 8.4% on a reported basis and 9.8% on an operational basis. Net revenues from the immunology portfolio were $6.264 billion, up 16.6% on a reported basis. Skyrizi generated $3.425 billion and Rinvoq generated $1.718 billion.

2. 02

   AbbVie said GAAP diluted EPS for Q1 fell 6.5% to $0.72, while adjusted diluted EPS rose 6.5% to $2.46. The company cited an unfavorable impact of $0.13 per share from acquired IPR&D and milestones expense.

3. 03

   The company said net revenues from its aesthetics portfolio for Q1 were $1.102 billion, down 11.7% on a reported basis and 10.2% on an operational basis. Botox Cosmetic net revenues were $556 million, and Juvederm net revenues were $231 million.

4. 04

   AbbVie said it raised its adjusted diluted EPS guidance for full-year 2025 to $12.09 - $12.29 from the prior range of $11.99 - $12.19. The guidance includes an unfavorable impact of $0.13 per share from acquired IPR&D and milestones expense incurred through Q1, and excludes expense incurred after Q1.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.